Short PDE4D Isoform Targeting Against Antiandrogen Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, particularly in intermediate to high-risk localized disease, face challenges due to the unpredictability of tumor foci and the development of androgen-independent phenotypes, with existing methods failing to effectively target the molecular heterogeneity of the disease.
Innovation Solution
A composition comprising agents that specifically reduce the expression of short PDE4D isoforms (PDE4D1, PDE4D2, and PDE4D6) in combination with antiandrogen therapy to enhance treatment efficacy and prevent recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If androgen ablation therapy is used to treat prostate cancer, then remission is achieved in 80-90% of patients, but androgen-independent phenotype emerges after remission leading to disease progression
Solution Approach 1:
The patent applies preliminary action by reducing PDE4D isoform expression before androgen ablation therapy is administered. This preemptive approach targets the molecular mechanisms that will later enable androgen-independence, thereby extending progression-free survival while maintaining the high remission rates achieved by standard therapy.
Solution Approach 2:
The patent employs parameter changes by specifically targeting and reducing the expression levels of PDE4D isoforms (PDE4D1, PDE4D2, PDE4D6). This molecular parameter modification prevents the development of androgen-independence, thereby extending the duration of treatment effectiveness without compromising initial remission achievement.
2Ease of operation
If PSA testing is used to diagnose prostate cancer, then screening is simplified, but false-positives occur in around 70% of men with raised PSA levels
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic approach into multiple molecular markers beyond PSA alone. By measuring specific PDE4D isoform expression levels in combination with PSA, the system maintains operational simplicity while significantly improving diagnostic accuracy and reducing false-positive rates through more precise tumor-specific detection.
Solution Approach 2:
The patent employs composite materials by creating a composite diagnostic signature that combines PSA levels with PDE4D isoform expression profiles. This multi-marker approach preserves the ease of PSA testing while enhancing measurement precision through the additive information from PDE4D markers, thereby reducing false-positive diagnoses.
3Productivity
If standard antiandrogen therapy is administered to prostate cancer patients, then initial response is achieved, but tumor heterogeneity leads to unpredictable treatment outcomes and recurrence
Solution Approach 1:
The patent applies local quality by targeting specific molecular subtypes within the heterogeneous tumor population. By reducing PDE4D isoform expression specifically in cancer cells while sparing normal tissue, the treatment achieves consistent anti-tumor effects across different tumor foci, thereby improving both productivity and reliability despite tumor heterogeneity.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular expression profile of PDE4D isoforms in response to antiandrogen therapy. This dynamic parameter adjustment prevents adaptive resistance mechanisms in heterogeneous tumors, ensuring consistent treatment response and reducing recurrence across diverse patient populations.
Data Source
Figure 1
AI summary
The invention relates to a product for use in the treatment, prevention or amelioration of prostate cancer in a subject in need thereof, wherein the product reduces the expression of a short PDE4D isoform such as PDE4D1, PDE4D2 and/or PDE4D6. The product may for example be a dominant-negative form of a short PDE4D isoform a proteolysis targeting chimera specifically targeting a short PDE4D isoform or a small RNA for targeting short isoform PDE4D expression.